Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Regeneron Pharmaceuticals is initiating a Phase 2 study titled A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of ANGPTL3 Inhibition With Either Small-Interfering RNA Alone or in Combination With an ANGPTL3 Antibody in Participants With Diabetic Kidney Disease. The study aims to evaluate the safety and effectiveness of ANGPTL3 inhibitors, specifically ALN-ANG3 and evinacumab, in treating diabetic kidney disease.
The study involves testing two experimental drugs, ALN-ANG3 and evinacumab, which are designed to inhibit ANGPTL3, a protein linked to lipid metabolism and potentially beneficial for diabetic kidney disease patients.
This interventional study is randomized and employs a parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are all blinded. The primary purpose is treatment-focused.
The study is not yet recruiting as of the last update on December 7, 2025. It was first submitted on November 21, 2025. These dates are crucial as they indicate the study’s timeline and readiness to commence.
Regeneron’s study could significantly impact its stock performance and investor sentiment by potentially offering a new treatment avenue for diabetic kidney disease. Success in this study could position Regeneron favorably against competitors in the pharmaceutical industry.
The study is ongoing, with further details available on the ClinicalTrials portal.
To learn more about REGN’s potential, visit the Regeneron Pharmaceuticals drug pipeline page.